| Authors: |
Smitheman KN; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Severson TM; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Rajapurkar SR; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., McCabe MT; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Karpinich N; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Foley J; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Pappalardi MB; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Hughes A; Target Sciences, GlaxoSmithKline, Collegeville, PA, USA., Halsey W; Target Sciences, GlaxoSmithKline, Collegeville, PA, USA., Thomas E; Target Sciences, GlaxoSmithKline, Collegeville, PA, USA., Traini C; Target Sciences, GlaxoSmithKline, Collegeville, PA, USA., Federowicz KE; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Laraio J; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Mobegi F; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Ferron-Brady G; Clinical Pharmacology and Modeling Sciences, GlaxoSmithKline, Collegeville, PA, USA., Prinjha RK; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Carpenter CL; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Kruger RG; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA., Wessels L; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of EEMCS, Delft University of Technology, the Netherlands., Mohammad HP; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA helai.x.mohammad@gsk.com. |
